Why the study?
Does catheter ablation reduce mortality in patients with sarcoidosis-related ventricular tachycardia compared to medical therapy alone?
Does catheter ablation reduce mortality in patients with sarcoidosis-related ventricular tachycardia compared to medical therapy alone?
Catheter ablation for sarcoidosis-related VT shows a trend toward lower mortality compared to medical therapy alone, but carries a notable 9.1% complication rate.
Ablation may be considered in refractory sarcoidosis VT despite 9.1% complications; hypothesis-generating and requires RCTs before practice change.
Compared to patients with sarcoidosis-related VT who received medical therapy alone, those who underwent CA have a trend for a lower mortality rate despite procedure-related complications occurring as high as 9.1%. Additional studies are recommended to better evaluate the benefits and risks of VT ablation in this group.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: